According to Cognitive Market Research, the global Bevacizumab market size will be USD 7158.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 9.70% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 2863.44 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2147.58 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1646.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 357.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 143.17 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
The Injection held the highest Bevacizumab market revenue share in 2024.
